Aura Biosciences, Inc. Increase Decrease In Operating Lease Liability
Aura Biosciences, Inc. (AURA) reported Increase Decrease In Operating Lease Liability of -$783.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- Aura Biosciences, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$397.00K.
- Aura Biosciences, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$386.00K.
- Aura Biosciences, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$377.00K.
- Aura Biosciences, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$358.00K, a 816.00% decline year-over-year.
- Aura Biosciences, Inc. increase decrease in operating lease liability for fiscal 2025 was -$1.39M.
- Aura Biosciences, Inc. increase decrease in operating lease liability for fiscal 2024 was -$788.00K.
- Aura Biosciences, Inc. increase decrease in operating lease liability for fiscal 2023 was -$1.32M.
- Aura Biosciences, Inc. increase decrease in operating lease liability for fiscal 2022 was -$744.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$397.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$783.00K 10-Q · filed 2026-08-11 | -$1.16M derived: sum of 3 quarters · filed 2026-08-11 | -$1.52M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$386.00K 10-Q · filed 2026-05-11 | -$763.00K derived: sum of 2 quarters · filed 2026-05-11 | -$1.12M derived: sum of 3 quarters · filed 2026-05-11 | -$1.45M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$377.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$735.00K derived: sum of 2 quarters · filed 2026-03-30 | -$1.07M derived: sum of 3 quarters · filed 2026-08-11 | -$1.39M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$358.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$690.00K derived: sum of 2 quarters · filed 2026-08-11 | -$1.01M 10-Q · filed 2025-11-13 | -$1.33M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$332.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$657.00K 10-Q · filed 2026-08-11 | -$972.00K derived: sum of 3 quarters · filed 2026-08-11 | -$922.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$325.00K 10-Q · filed 2026-05-11 | -$640.00K derived: sum of 2 quarters · filed 2026-05-11 | -$590.00K derived: sum of 3 quarters · filed 2026-05-11 | -$876.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$315.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$265.00K derived: sum of 2 quarters · filed 2026-03-30 | -$551.00K derived: sum of 3 quarters · filed 2026-03-30 | -$788.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$236.00K derived: sum of 2 quarters · filed 2025-11-13 | -$473.00K 10-Q · filed 2025-11-13 | -$1.11M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$286.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$523.00K 10-Q · filed 2025-08-13 | -$1.16M derived: sum of 3 quarters · filed 2025-08-13 | -$1.40M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$237.00K 10-Q · filed 2025-05-15 | -$870.00K derived: sum of 2 quarters · filed 2025-05-15 | -$1.12M derived: sum of 3 quarters · filed 2025-05-15 | -$1.34M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$633.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$879.00K derived: sum of 2 quarters · filed 2025-03-24 | -$1.10M derived: sum of 3 quarters · filed 2025-03-24 | -$1.32M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$246.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$470.00K derived: sum of 2 quarters · filed 2024-11-12 | -$689.00K 10-Q · filed 2024-11-12 | -$939.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$224.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$443.00K 10-Q · filed 2024-08-08 | -$693.00K derived: sum of 3 quarters · filed 2024-08-08 | -$895.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$219.00K 10-Q · filed 2024-05-09 | -$469.00K derived: sum of 2 quarters · filed 2024-05-09 | -$671.00K derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | -$250.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$452.00K derived: sum of 2 quarters · filed 2024-03-27 | -$744.00K 10-K · filed 2024-03-27 | |
| 2022-09-30 | -$202.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$494.00K 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | -$292.00K 10-Q · filed 2023-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |